Aquestive Therapeutics, Inc. (AQST)

NASDAQ: AQST · IEX Real-Time Price · USD
0.936
+0.026 (2.89%)
At close: Dec 9, 2022 4:00 PM
0.920
-0.016 (-1.72%)
After-hours: Dec 9, 2022 6:30 PM EST
2.89%
Market Cap 49.28M
Revenue (ttm) 48.08M
Net Income (ttm) -71.00M
Shares Out 53.42M
EPS (ttm) -1.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 83,150
Open 0.91
Previous Close 0.91
Day's Range 0.91 - 0.943
52-Week Range 0.618 - 6.25
Beta 2.79
Analysts Buy
Price Target 5.61 (+499.2%)
Earnings Date Nov 1, 2022

About AQST

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with che... [Read more]

Industry Pharmaceuticals
IPO Date Jul 25, 2018
Employees 157
Stock Exchange NASDAQ
Ticker Symbol AQST
Full Company Profile

Financial Performance

In 2021, AQST's revenue was $50.83 million, an increase of 10.87% compared to the previous year's $45.85 million. Losses were -$70.54 million, 26.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for AQST stock is "Buy." The 12-month stock price forecast is 5.61, which is an increase of 499.17% from the latest price.

Price Target
$5.61
(499.17% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray Peer-reviewed data indicates that food significantly decreases and delays the a...

1 week ago - GlobeNewsWire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WARREN, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying ...

3 weeks ago - GlobeNewsWire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual fil...

WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying ...

1 month ago - GlobeNewsWire

Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 23.33% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

WARREN, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying ...

1 month ago - GlobeNewsWire

Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.

WARREN, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying ...

1 month ago - GlobeNewsWire

Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 an...

WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying ...

1 month ago - GlobeNewsWire

Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film

WARREN, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying ...

1 month ago - GlobeNewsWire

Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival

Source: Rob Byron / Shutterstock.com Aquestive Therapeutics (NASDAQ: AQST ) stock is taking off on Tuesday as investors react to positive clinical trial data from the pharmaceutical company. Aquestive T...

2 months ago - InvestorPlace

Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®

WARREN, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and ...

2 months ago - GlobeNewsWire

Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board

WARREN, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and ...

2 months ago - GlobeNewsWire

Aquestive Therapeutics to Participate in Two Investor Conferences in September

WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and p...

3 months ago - GlobeNewsWire

Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and p...

3 months ago - GlobeNewsWire

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 12.20% and 32.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

WARREN, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and p...

4 months ago - GlobeNewsWire

Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference

WARREN, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and p...

4 months ago - GlobeNewsWire

Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real...

WARREN, N.J., July 11, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and p...

4 months ago - GlobeNewsWire

Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinep...

WARREN, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and p...

5 months ago - GlobeNewsWire

Aquestive Therapeutics, Inc. Announces Closing of $8.5 Million Registered Direct Offering

WARREN, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and p...

6 months ago - GlobeNewsWire

Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering

WARREN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and p...

6 months ago - GlobeNewsWire

Aquestive Therapeutics Announces CEO Transition

WARREN, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and pr...

6 months ago - GlobeNewsWire

Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference

WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and pr...

6 months ago - GlobeNewsWire

Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 28.89% and 25.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

WARREN, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and pr...

7 months ago - GlobeNewsWire

Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital

WARREN, N.J., April 13, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and ...

7 months ago - GlobeNewsWire